Completed PHASE2 INTERVENTIONAL 2-arm NCT00391560

Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia

Sponsor: AEterna Zentaris

Conditions Leukemia

Interventions perifosine

Updated 8 times since 2017 Last updated: Mar 12, 2018 Started: Oct 31, 2006 Primary completion: Oct 31, 2010 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Leukemia and is currently completed. AEterna Zentaris leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Mar 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Mar 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AEterna Zentaris

Data source: AEterna Zentaris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.